이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

istituto biochimico italiano giovanni lorenzini s.p.a. - clindamicina - clindamicina

이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

diaco biofarmaceutici s.r.l. - mannitolo - mannitolo

이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

hikma italia s.p.a. - clindamicina - clindamicina

이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

bioindustria laboratorio italiano medicinali s.p.a. - clindamicina - clindamicina

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosfato tedizolid - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - infezioni acquisite in comunità - antibatterici per uso sistemico, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 e 5. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibatterici per uso sistemico, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - compresse rivestite con film - linezolidum 600 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum a corresp. natrium max. 3.4 mg, magnesii stearas, Überzug: cera carnauba, hypromellosum, e 171, macrogolum 400, pro compresso obducto. - malattie infettive - synthetika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - granulato per sospensione orale - linezolidum 20 mg, saccharum 210.58 mg, acidum citricum, natrii citras anhydricus, cellulosum microcristallinum, carmellosum natricum, aspartamum 7 mg, xanthani gummi, mannitolum, e 211 2 mg, aromatica (orange) cum ethanolum 0.2 mg et maltodextrinum, silica colloidalis anhydrica, aromatica (pfefferminze), aromatica (vanille) cum propylenglycolum et alcohol benzylicus et maltodextrinum, natrii chloridum, sorbitolum 8.76 mg, fructosum 3.36 mg, maltodextrinum, acidum glycyrrhizinicum, ammonii glycyrrhizas, triglycerida media, aromatica (orangencrème) cum ethanolum et amylum modificatum et maltodextrinum, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 2.279 mg. - malattie infettive - synthetika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - soluzione per infusione - linezolidum 2 mg, natrii citras dihydricus corresp. natrium 0.38 mg, acidum citricum, glucosum monohydricum corresp. glucosum 45.7 mg, natrii hydroxidum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - malattie infettive - synthetika